Sanofi has opened a new UK Headquarters, based at Thames Valley Park in Reading, Berkshire.
The company welcomed Matt Hancock, secretary of state for health and social care, to open the “state of the art” facility, along side Paul Hudson, chief executive officer of Sanofi and Hugo Fry, UK’s managing director.
The new 70,000 square ft. office facility marks a £37 million investment to Reading and will be the new base for 500 of the 1,200 employees in the UK.
“We are delighted to unveil our new headquarters and it has been an honour to welcome the Rt Hon Matt Hancock, secretary of state for health and social care, to today’s event,” says Hugo Fry, managing director at Sanofi in the UK.
He continued, “Thames Valley Park is well located and connected, but also home to global technology leaders and one of the best places for life sciences in the world. Just as delivering the best outcomes for the one million UK patients we support every month is important to us, we paid particular attention to designing a space that promotes the health and wellbeing of our employees.”
The company revealed that it is actively seeking to recruit at least 50 new roles in the coming months, in addition to ten graduate students via its new Aspiring Leaders programme.
By Anna Smith
Source: Pharma Times
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
